436 related articles for article (PubMed ID: 30923826)
1. EZHIP/CXorf67 mimics K27M mutated oncohistones and functions as an intrinsic inhibitor of PRC2 function in aggressive posterior fossa ependymoma.
Hübner JM; Müller T; Papageorgiou DN; Mauermann M; Krijgsveld J; Russell RB; Ellison DW; Pfister SM; Pajtler KW; Kool M
Neuro Oncol; 2019 Jul; 21(7):878-889. PubMed ID: 30923826
[TBL] [Abstract][Full Text] [Related]
2. Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas.
Pajtler KW; Wen J; Sill M; Lin T; Orisme W; Tang B; Hübner JM; Ramaswamy V; Jia S; Dalton JD; Haupfear K; Rogers HA; Punchihewa C; Lee R; Easton J; Wu G; Ritzmann TA; Chapman R; Chavez L; Boop FA; Klimo P; Sabin ND; Ogg R; Mack SC; Freibaum BD; Kim HJ; Witt H; Jones DTW; Vo B; Gajjar A; Pounds S; Onar-Thomas A; Roussel MF; Zhang J; Taylor JP; Merchant TE; Grundy R; Tatevossian RG; Taylor MD; Pfister SM; Korshunov A; Kool M; Ellison DW
Acta Neuropathol; 2018 Aug; 136(2):211-226. PubMed ID: 29909548
[TBL] [Abstract][Full Text] [Related]
3. PFA ependymoma-associated protein EZHIP inhibits PRC2 activity through a H3 K27M-like mechanism.
Jain SU; Do TJ; Lund PJ; Rashoff AQ; Diehl KL; Cieslik M; Bajic A; Juretic N; Deshmukh S; Venneti S; Muir TW; Garcia BA; Jabado N; Lewis PW
Nat Commun; 2019 May; 10(1):2146. PubMed ID: 31086175
[TBL] [Abstract][Full Text] [Related]
4. H3 K27M and EZHIP Impede H3K27-Methylation Spreading by Inhibiting Allosterically Stimulated PRC2.
Jain SU; Rashoff AQ; Krabbenhoft SD; Hoelper D; Do TJ; Gibson TJ; Lundgren SM; Bondra ER; Deshmukh S; Harutyunyan AS; Juretic N; Jabado N; Harrison MM; Lewis PW
Mol Cell; 2020 Nov; 80(4):726-735.e7. PubMed ID: 33049227
[TBL] [Abstract][Full Text] [Related]
5. EZH2 inhibitory protein (EZHIP/Cxorf67) expression correlates strongly with H3K27me3 loss in posterior fossa ependymomas and is mutually exclusive with H3K27M mutations.
Nambirajan A; Sharma A; Rajeshwari M; Boorgula MT; Doddamani R; Garg A; Suri V; Sarkar C; Sharma MC
Brain Tumor Pathol; 2021 Jan; 38(1):30-40. PubMed ID: 33130928
[TBL] [Abstract][Full Text] [Related]
6. EZHIP: a new piece of the puzzle towards understanding pediatric posterior fossa ependymoma.
Jenseit A; Camgöz A; Pfister SM; Kool M
Acta Neuropathol; 2022 Jan; 143(1):1-13. PubMed ID: 34762160
[TBL] [Abstract][Full Text] [Related]
7. Elevated CXorf67 Expression in PFA Ependymomas Suppresses DNA Repair and Sensitizes to PARP Inhibitors.
Han J; Yu M; Bai Y; Yu J; Jin F; Li C; Zeng R; Peng J; Li A; Song X; Li H; Wu D; Li L
Cancer Cell; 2020 Dec; 38(6):844-856.e7. PubMed ID: 33186520
[TBL] [Abstract][Full Text] [Related]
8. Common molecular features of H3K27M DMGs and PFA ependymomas map to hindbrain developmental pathways.
Pun M; Pratt D; Nano PR; Joshi PK; Jiang L; Englinger B; Rao A; Cieslik M; Chinnaiyan AM; Aldape K; Pfister S; Filbin MG; Bhaduri A; Venneti S
Acta Neuropathol Commun; 2023 Feb; 11(1):25. PubMed ID: 36759899
[TBL] [Abstract][Full Text] [Related]
9. Immunostaining of Increased Expression of Enhancer of Zeste Homolog 2 (EZH2) in Diffuse Midline Glioma H3K27M-Mutant Patients with Poor Survival.
Karlowee V; Amatya VJ; Takayasu T; Takano M; Yonezawa U; Takeshima Y; Sugiyama K; Kurisu K; Yamasaki F
Pathobiology; 2019; 86(2-3):152-161. PubMed ID: 31096221
[TBL] [Abstract][Full Text] [Related]
10. EZHIP is a specific diagnostic biomarker for posterior fossa ependymomas, group PFA and diffuse midline gliomas H3-WT with EZHIP overexpression.
Antin C; Tauziède-Espariat A; Debily MA; Castel D; Grill J; Pagès M; Ayrault O; Chrétien F; Gareton A; Andreiuolo F; Lechapt E; Varlet P
Acta Neuropathol Commun; 2020 Nov; 8(1):183. PubMed ID: 33153494
[No Abstract] [Full Text] [Related]
11. Structural basis of oncogenic histone H3K27M inhibition of human polycomb repressive complex 2.
Justin N; Zhang Y; Tarricone C; Martin SR; Chen S; Underwood E; De Marco V; Haire LF; Walker PA; Reinberg D; Wilson JR; Gamblin SJ
Nat Commun; 2016 Apr; 7():11316. PubMed ID: 27121947
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous disruption of PRC2 and enhancer function underlies histone H3.3-K27M oncogenic activity in human hindbrain neural stem cells.
Brien GL; Bressan RB; Monger C; Gannon D; Lagan E; Doherty AM; Healy E; Neikes H; Fitzpatrick DJ; Deevy O; Grant V; Marqués-Torrejón MA; Alfazema N; Pollard SM; Bracken AP
Nat Genet; 2021 Aug; 53(8):1221-1232. PubMed ID: 34294917
[TBL] [Abstract][Full Text] [Related]
13. CATACOMB: An endogenous inducible gene that antagonizes H3K27 methylation activity of Polycomb repressive complex 2 via an H3K27M-like mechanism.
Piunti A; Smith ER; Morgan MAJ; Ugarenko M; Khaltyan N; Helmin KA; Ryan CA; Murray DC; Rickels RA; Yilmaz BD; Rendleman EJ; Savas JN; Singer BD; Bulun SE; Shilatifard A
Sci Adv; 2019 Jul; 5(7):eaax2887. PubMed ID: 31281901
[TBL] [Abstract][Full Text] [Related]
14. Regulation of histone methylation by automethylation of PRC2.
Wang X; Long Y; Paucek RD; Gooding AR; Lee T; Burdorf RM; Cech TR
Genes Dev; 2019 Oct; 33(19-20):1416-1427. PubMed ID: 31488576
[TBL] [Abstract][Full Text] [Related]
15. EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas.
Mohammad F; Weissmann S; Leblanc B; Pandey DP; Højfeldt JW; Comet I; Zheng C; Johansen JV; Rapin N; Porse BT; Tvardovskiy A; Jensen ON; Olaciregui NG; Lavarino C; Suñol M; de Torres C; Mora J; Carcaboso AM; Helin K
Nat Med; 2017 Apr; 23(4):483-492. PubMed ID: 28263309
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of histone 3 lysine 27 trimethylation (H3K27me3) and enhancer of Zest 2 (EZH2) in pediatric glial and glioneuronal tumors shows decreased H3K27me3 in H3F3A K27M mutant glioblastomas.
Venneti S; Garimella MT; Sullivan LM; Martinez D; Huse JT; Heguy A; Santi M; Thompson CB; Judkins AR
Brain Pathol; 2013 Sep; 23(5):558-64. PubMed ID: 23414300
[TBL] [Abstract][Full Text] [Related]
17. H3 K27M mutations are extremely rare in posterior fossa group A ependymoma.
Ryall S; Guzman M; Elbabaa SK; Luu B; Mack SC; Zapotocky M; Taylor MD; Hawkins C; Ramaswamy V
Childs Nerv Syst; 2017 Jul; 33(7):1047-1051. PubMed ID: 28623522
[TBL] [Abstract][Full Text] [Related]
18. Metabolic Regulation of the Epigenome Drives Lethal Infantile Ependymoma.
Michealraj KA; Kumar SA; Kim LJY; Cavalli FMG; Przelicki D; Wojcik JB; Delaidelli A; Bajic A; Saulnier O; MacLeod G; Vellanki RN; Vladoiu MC; Guilhamon P; Ong W; Lee JJY; Jiang Y; Holgado BL; Rasnitsyn A; Malik AA; Tsai R; Richman CM; Juraschka K; Haapasalo J; Wang EY; De Antonellis P; Suzuki H; Farooq H; Balin P; Kharas K; Van Ommeren R; Sirbu O; Rastan A; Krumholtz SL; Ly M; Ahmadi M; Deblois G; Srikanthan D; Luu B; Loukides J; Wu X; Garzia L; Ramaswamy V; Kanshin E; Sánchez-Osuna M; El-Hamamy I; Coutinho FJ; Prinos P; Singh S; Donovan LK; Daniels C; Schramek D; Tyers M; Weiss S; Stein LD; Lupien M; Wouters BG; Garcia BA; Arrowsmith CH; Sorensen PH; Angers S; Jabado N; Dirks PB; Mack SC; Agnihotri S; Rich JN; Taylor MD
Cell; 2020 Jun; 181(6):1329-1345.e24. PubMed ID: 32445698
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma.
Lewis PW; Müller MM; Koletsky MS; Cordero F; Lin S; Banaszynski LA; Garcia BA; Muir TW; Becher OJ; Allis CD
Science; 2013 May; 340(6134):857-61. PubMed ID: 23539183
[TBL] [Abstract][Full Text] [Related]
20. Polycomb repressive complex's evolutionary conserved function: the role of EZH2 status and cellular background.
Gall Trošelj K; Novak Kujundzic R; Ugarkovic D
Clin Epigenetics; 2016; 8():55. PubMed ID: 27239242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
